ScholarLens Back to search
2012•Journal of Chengdu Medical CollegeRequires access

Metformin and insulin sensitizerrosiglitazone combination in improving nonalcoholic fatty liver disease

YE Qiu-tao

Open publisher page 0 citations

Abstract

Objective to study the combined use of metformin and insulin sensitizer rosiglitazone to improve nonalcoholic fatty liver disease(NAFLD).Method Eight-two cases of NAFLD were slected from Jan 2009 to Jan 2012,including 42 cases with combined metformin and rosiglitazone treatmentgroup,and 42 cases with metformin only group.The therapeutic effects were evaluated 6 months after treatments without other hepatoprotective means Results Based on NAFLD images and the serum biochemical related indicators,The combined treatment of metformin and rosiglitation was significantly better than metformin alone(P0.05).Conclusion metformin and insulin sensitizer rosiglitazone in the treatment of NAFLD could have better clinical outcomes with safety.

About this research paper

What this paper is about

Objective to study the combined use of metformin and insulin sensitizer rosiglitazone to improve nonalcoholic fatty liver disease(NAFLD).Method Eight-two cases of NAFLD were slected from Jan 2009 to Jan 2012,including 42 cases with combined metformin and rosiglitazone treatmentgroup,and 42 cases with metformin only group.The therapeutic effects were evaluated 6 months after treatments without other hepatoprotective means Results Based on NAFLD images and the serum biochemical related indicators,The combined treatment of metformin and rosiglitation was significantly better than metformin alone(P0.05).Conclusion metformin and insulin sensitizer rosiglitazone in the treatment of NAFLD could have better clinical outcomes with safety.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective to study the combined use of metformin and insulin sensitizer rosiglitazone to improve nonalcoholic fatty liver disease(NAFLD).Method Eight-two cases of NAFLD were slected from Jan 2009 to Jan 2012,including 42 cases with combined metformin and rosiglitazone treatmentgroup,and 42 cases with metformin only group.The therapeutic effects were evaluated 6 months after treatments without other hepatoprotective means Results Based on NAFLD images and the serum biochemical related indicators,The combined treatment of metformin and rosiglitation was significantly better than metformin alone(P0.05).Conclusion metformin and insulin sensitizer rosiglitazone in the treatment of NAFLD could have better clinical outcomes with safety.

Key concepts: Metformin, Rosiglitazone, Nonalcoholic fatty liver disease, Medicine, Internal medicine, Insulin, Fatty liver, Gastroenterology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Metformin and insulin sensitizerrosiglitazone combination in improving nonalcoholic fatty liver disease — Research Paper | ScholarLens